Cibus, Inc.

NasdaqCM:CBUS Stock Report

Market Cap: US$117.4m

Cibus Valuation

Is CBUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CBUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CBUS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CBUS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBUS?

Key metric: As CBUS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CBUS. This is calculated by dividing CBUS's market cap by their current revenue.
What is CBUS's PS Ratio?
PS Ratio27.8x
SalesUS$4.15m
Market CapUS$117.39m

Price to Sales Ratio vs Peers

How does CBUS's PS Ratio compare to its peers?

The above table shows the PS ratio for CBUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average18.2x
IMAB I-Mab
24.1x53.4%US$77.6m
QURE uniQure
10x35.8%US$277.8m
SAGE Sage Therapeutics
2.8x32.1%US$300.4m
VTVT vTv Therapeutics
36.1xn/aUS$46.5m
CBUS Cibus
27.8x64.6%US$117.4m

Price-To-Sales vs Peers: CBUS is expensive based on its Price-To-Sales Ratio (27.8x) compared to the peer average (18.2x).

Price to Sales Ratio vs Industry

How does CBUS's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$110.46b
BIIB Biogen
2.4x1.3%US$22.73b
MRNA Moderna
2.9x6.8%US$14.22b
INCY Incyte
3.3x8.9%US$13.69b
CBUS 27.8xIndustry Avg. 10.1xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CBUS is expensive based on its Price-To-Sales Ratio (27.8x) compared to the US Biotechs industry average (10.1x).

Price to Sales Ratio vs Fair Ratio

What is CBUS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBUS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio27.8x
Fair PS Ratio24.9x

Price-To-Sales vs Fair Ratio: CBUS is expensive based on its Price-To-Sales Ratio (27.8x) compared to the estimated Fair Price-To-Sales Ratio (24.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CBUS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.37
US$19.13
+337.6%
34.9%US$25.00US$8.00n/a4
Nov ’25US$4.40
US$19.13
+334.7%
34.9%US$25.00US$8.00n/a4
Oct ’25US$3.53
US$19.13
+441.8%
34.9%US$25.00US$8.00n/a4
Sep ’25US$6.77
US$19.75
+191.7%
35.3%US$25.00US$8.00n/a4
Aug ’25US$9.16
US$22.75
+148.4%
10.9%US$25.00US$19.00n/a4
Jul ’25US$9.27
US$23.00
+148.1%
12.3%US$25.00US$19.00n/a3
Jun ’25US$14.46
US$23.00
+59.1%
12.3%US$25.00US$19.00n/a3
May ’25US$17.11
US$23.00
+34.4%
12.3%US$25.00US$19.00n/a3
Apr ’25US$20.37
US$22.00
+8.0%
19.3%US$25.00US$16.00n/a3
Mar ’25US$17.99
US$22.00
+22.3%
19.3%US$25.00US$16.00n/a3
Feb ’25US$17.25
US$22.00
+27.5%
19.3%US$25.00US$16.00n/a3
Jan ’25US$19.64
US$22.00
+12.0%
19.3%US$25.00US$16.00n/a3
Dec ’24US$13.87
US$22.00
+58.6%
19.3%US$25.00US$16.00n/a3
Nov ’24US$10.78
US$25.33
+135.0%
14.5%US$30.00US$21.00US$4.403
Oct ’24US$18.22
US$25.50
+40.0%
17.6%US$30.00US$21.00US$3.532
Sep ’24US$14.91
US$25.50
+71.0%
17.6%US$30.00US$21.00US$6.772
Aug ’24US$20.26
US$24.00
+18.5%
25.0%US$30.00US$18.00US$9.162
Jul ’24US$10.50
US$34.00
+223.8%
47.1%US$50.00US$18.00US$9.272
Jun ’24US$26.05
US$36.25
+39.2%
37.9%US$50.00US$22.50US$14.462
May ’24US$15.75
US$36.25
+130.2%
37.9%US$50.00US$22.50US$17.112
Apr ’24US$17.00
US$36.25
+113.2%
37.9%US$50.00US$22.50US$20.372
Nov ’23US$7.16
US$275.00
+3,740.8%
81.8%US$500.00US$50.00US$10.782

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%